EUS-guided fine needle biopsy of pancreatic masses can yield true histology

Ji Young Bang, Shantel Hebert-Magee, Udayakumar Navaneethan, Muhammad K Hasan, Robert Hawes, Shyam Varadarajulu, Ji Young Bang, Shantel Hebert-Magee, Udayakumar Navaneethan, Muhammad K Hasan, Robert Hawes, Shyam Varadarajulu

No abstract available

Keywords: endoscopic ultrasonography; pancreatic cancer.

Conflict of interest statement

Competing interests: SV: consultant for olympusm medical systems corporation and Boston scientific corporation. RH: consultant for olympus medical systems corporation and boston scientific corporation.

Figures

Figure 1
Figure 1
The 22G Franseen design with a crown-shaped needle tip revealing the three symmetrical planes for histological core tissue acquisition (A). The standard bevel needle used at fine needle aspiration for procurement of cytological aspirates (B).
Figure 2
Figure 2
Flow diagram of patients recruited for participation in the randomised trial. FNA, fine needle aspiration; FNB, fine needle biopsy; EUS, endoscopic-ultrasound.
Figure 3
Figure 3
Rapid onsite evaluation of a pancreatic head mass biopsied using the Franseen needle reveals a cellular specimen comprising malignant cells, fibrosis and benign reactive ductal epithelium (A; Diff-Quik staining, 200×). The corresponding aspirate from a standard FNA needle reveals scattered malignant cells and with minimal fibrosis (B; Diff-Quik staining, 100×). H&E staining of pancreatic adenocarcinoma (100×) procured with the Franseen needle. Cores of exuberant dense desmoplastic fibrosis are seen entrapping malignant ductal epithelium and scattered benign residual acini on sections from the cell block (C). The corresponding image of a specimen from an FNA needle reveals minimal tumour cells and lack of any desmoplastic fibrosis (D). Digital image analysis reveals dense desmoplastic fibrosis (highlighted yellow) surrounding malignant (highlighted blue) ductal groups and foci of residual benign acini (E). The corresponding image of a specimen from an FNA needle reveals fewer tumour cells, lack of any significant architecture and a minute fragment of fibrosis (F). FNA, fine needle aspiration.

References

    1. Chantrill LA, Nagrial AM, Watson C, et al. . Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res 2015;21:2029–37. 10.1158/1078-0432.CCR-15-0426
    1. Varadarajulu S, Tamhane A, Eloubeidi MA. Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. Gastrointest Endosc 2005;62:728–36. 10.1016/j.gie.2005.06.051
    1. Hébert-Magee S, Bae S, Varadarajulu S, et al. . The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. Cytopathology 2013;24:159–71. 10.1111/cyt.12071
    1. Hingorani SR, Harris WP, Beck JT, et al. . Phase Ib Study of PEGylated Recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res 2016;22:2848–54. 10.1158/1078-0432.CCR-15-2010
    1. Bang JY, Hebert-Magee S, Hasan MK, et al. . Endoscopic ultrasonography-guided biopsy using a Franseen needle design: initial assessment. Dig Endosc 2017;29:338–46. 10.1111/den.12769
    1. Kandel P, Tranesh G, Nassar A, et al. . EUS-guided fine needle biopsy sampling using a novel fork-tip needle: a case-control study. Gastrointest Endosc 2016;84:1034–9. 10.1016/j.gie.2016.03.1405
    1. Han P, Che D, Pallav K, et al. . Models of the cutting edge geometry of medical needles with applications to needle design. Int J Mech Sci 2012;65:157–67. 10.1016/j.ijmecsci.2012.09.014
    1. Sato N, Cheng XB, Kohi S, et al. . Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharm Sin B 2016;6:101–5. 10.1016/j.apsb.2016.01.002
    1. Jacobetz MA, Chan DS, Neesse A, et al. . Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62:112–20. 10.1136/gutjnl-2012-302529
    1. Bournet B, Muscari F, Buscail C, et al. . KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma. Clin Transl Gastroenterol 2016;7:e157 10.1038/ctg.2016.18
    1. Kopelman Y, Marmor S, Ashkenazi I, et al. . Value of EUS-FNA cytological preparations compared with cell block sections in the diagnosis of pancreatic solid tumours. Cytopathology 2011;22:174–8. 10.1111/j.1365-2303.2010.00766.x
    1. Varadarajulu S, Bang JY, Holt BA, et al. . The 25-gauge EUS-FNA needle: good for on-site but poor for off-site evaluation? Results of a randomized trial. Gastrointest Endosc 2014;80:1056–63. 10.1016/j.gie.2014.05.304

Source: PubMed

Подписаться